Preliminary activity on the pyrolysis of a plastic based solid recovered fuel

Plastic is a versatile, lightweight, resistant, and inexpensive material, and an increase of its global demand has been observed in the last years (from 299 milion tonnes in 2013 to 348 in 2017) [1], with the dominant role played by the packaging sector, which absorbs almost 40% of the overall production. Management of post–consumer plastic packaging waste poses a serious environmental problem, and a number of strategies have been devised to reuse/recover these materials, mainly with the aim of recovering useful materials and avoiding landfilling. Among these strategies, pyrolysis can play a significant role for recovering useful products and energy from the post–selection mixed packaging waste, that is not amenable to other uses [1]. A large amount of studies has been developed to assess the possibility to convert waste plastic to oil by pyrolysis processes [1] either catalytic or non catalytic. Nevertheless, only a limited numbers of papers refer to the use of real plastic waste rather than simulated mixtures [2] even if the performances obtained are strongly influenced by the feedstock characteristics. Please click Additional Files below to see the full abstract

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty

Abstract Aims The aim of this study was to investigate prospectively the effect of sacubitril/valsartan in advanced heart failure (HF) patients in waiting list for heart transplantation (HT) and the effect on physical frailty (PF). Methods and results We treated 37 consecutive patients with advanced HF with sacubitril/valsartan. Patients were followed up until HT, device implant, or last follow‐up visit after 2 years of follow‐up. At baseline, mean New York Heart Association (NYHA) class was 3.1 ± 0.4, with 64.9% in NYHA III and 35.1% NYHA IIIB. Left ventricular ejection fraction was 23.5 ± 5.8%, VO2 max was 10.3 ± 2.3 mL/kg/min, cardiac index was 2.3 ± 0.5 L/min/m2, and N‐terminal pro‐brain natriuretic peptide (NT‐pro‐BNP) was 4943.0 ± 5326.8 pg/mL. After a mean follow‐up of 17.1 ± 4.4 months, no deaths were observed, but NYHA class improved significantly with 56.8% in NYHA II, 40.5% in NYHA III, and 2.7% in NYHA IIIB (P < 0.001). VO2 max and 6 min walk test (6MWT) increased, whereas pulmonary systolic blood pressure, E/E′, VE/VCO2 slope, and NT‐pro‐BNP decreased. At right heart catheterization performed after 1 year of follow‐up, cardiac index and pulmonary vascular resistance remained stable, while a decrease in systolic pulmonary artery pressure and pulmonary capillary wedge pressure is observed. Furosemide dosage decrease from 102.7 ± 69.4 to 78.7 ± 66.3 mg (P = 0.040). PF decreased from 3.35 ± 1.0 at baseline to 1.57 ± 1.3 at the end of follow‐up (P < 0.001), with a reduction in all PF domains. Conclusions Our study showed a rapid improvement in PF in HT waiting list patients treated with sacubitril/valsartan. The improvement in all PF domains was paralleled by VO2 and 6MWT increase and together with an NT‐pro‐BNP reduction constant over the follow‐up